A recent study from the Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy shows that “PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer.” This study was published in the 12 February 2015 issue of the Journal Cell [I.F:33] by Drs. Alberto Mantovani , Eduardo Bonavita and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Inflammation-mediated cancers: Cirsilol (3′,4′,5-trihydroxy-6,7-dimethoxyflavone), a flavone isolated from Achillea fragrantissima, increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation via down regulation of its target gene. Together, pharmacological formulations encompassing “Cirsilol or its analogues” may be used to treat patients suffering from inflammation-associated tumorigenesis.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based therapy for Inflammation-mediated cancers: Cirsilol (3′,4′,5-trihydroxy-6,7-dimethoxyflavone), a flavone isolated from Achillea fragrantissima, suppresses pulmonary hypertension via up increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation via down regulation of its target gene, 5/March/2015, 13.46, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Cirsilol increases the expression of PTX3
Amount: $500*